Skip to main content

Table 2 SVR rates between patients aged < 65 years and patients aged ≥ 65 years according to HCV genotype

From: The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients

 

Age < 65 (n= 319)

Age ≥ 65 (n= 108)

P valuea

SVR rate (Genotype 1)

41.5% (100/241)

40.7% (35/86)

0.899

SVR rate (Genotype 2)

89.7% (70/78)

86.4% (19/22)

0.703

  1. HCV hepatitis C virus; SVR sustained virological response; a Fisher's exact test
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us